Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AtriCure (ATRC) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for AtriCure (ATRC) over the last 17 years, with Q3 2025 value amounting to $147.9 million.

  • AtriCure's Cash & Equivalents rose 1345.0% to $147.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.9 million, marking a year-over-year increase of 1345.0%. This contributed to the annual value of $122.7 million for FY2024, which is 4555.92% up from last year.
  • Per AtriCure's latest filing, its Cash & Equivalents stood at $147.9 million for Q3 2025, which was up 1345.0% from $117.8 million recorded in Q2 2025.
  • Over the past 5 years, AtriCure's Cash & Equivalents peaked at $147.9 million during Q3 2025, and registered a low of $28.1 million during Q1 2022.
  • In the last 5 years, AtriCure's Cash & Equivalents had a median value of $77.3 million in 2023 and averaged $80.3 million.
  • In the last 5 years, AtriCure's Cash & Equivalents skyrocketed by 29226.32% in 2021 and then plummeted by 6704.03% in 2022.
  • Over the past 5 years, AtriCure's Cash & Equivalents (Quarter) stood at $43.7 million in 2021, then soared by 33.09% to $58.1 million in 2022, then skyrocketed by 45.11% to $84.3 million in 2023, then soared by 45.56% to $122.7 million in 2024, then increased by 20.49% to $147.9 million in 2025.
  • Its last three reported values are $147.9 million in Q3 2025, $117.8 million for Q2 2025, and $99.9 million during Q1 2025.